Atlas Trials

A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks

Clinical trial NCT07748000 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07748000
Sponsor
Liquidia Technologies, Inc.
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Start date
2026-10-26
Primary completion
2027-02-01
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.